Literature DB >> 10626520

Bone mineral density in patients with phenylketonuria.

J Zeman1, M Bayer, J Stepán.   

Abstract

Dual energy X-ray absorptiometry was performed in 44 patients with phenylketonuria (PKU) aged 6-29 y. The phenylalanine-restricted diet was based on a low-protein diet in combination with phenylalanine-free amino acid mixtures and phenylalanine-low casein hydrolysate in 32 patients. The 10 oldest patients were supplemented only with casein hydrolysate, and the youngest child received only the amino acid mixture. One patient has recently come off the diet. Bone mineral density (BMD) of the lumbar spine and total BMD were measured and expressed as Z-score, i.e. the difference between the BMD of the patient and the average BMD of sex- and age-matched controls divided by the standard deviation of the control group. Normal BMD was found in 24 (54%) patients. Lumbar spine BMD was decreased in 20 patients and total BMD was decreased in 14 patients. Z-scores of -1to 2.5 were found in 14 patients (32%) and Z-scores of <-2.5 in 6 patients (14%). No significant correlation was found between total or lumbar spine BMD and daily intake of phenylalanine from natural sources in the low-protein diet or the amount of phenylalanine-free amino acid mixtures per kg of body weight. A significant negative correlation was observed between both total and lumbar spine BMD Z-scores and the amount of casein hydrolysate supplementation per kg of body weight (r = - 0.45; y = 0.07 - 0.69x; p < 0.01). Long-lasting dietary restriction in patients with PKU may increase the risk of late complications of dietary therapy, such as osteoporosis or trace element deficiency. O Bone mineral density, osteoporosis, phenylalanine-low diet, phenylketonuria

Entities:  

Mesh:

Year:  1999        PMID: 10626520     DOI: 10.1080/080352599750030068

Source DB:  PubMed          Journal:  Acta Paediatr        ISSN: 0803-5253            Impact factor:   2.299


  20 in total

1.  Bone development in children and adolescents with PKU.

Authors:  A B Mendes; F F Martins; W M S Cruz; L E da Silva; C B M Abadesso; G T Boaventura
Journal:  J Inherit Metab Dis       Date:  2011-11-11       Impact factor: 4.982

2.  Elevated plasma phenylalanine concentrations may adversely affect bone status of phenylketonuric mice.

Authors:  S Yannicelli; D M Medeiros
Journal:  J Inherit Metab Dis       Date:  2002-09       Impact factor: 4.982

3.  Nutritional Management of Phenylketonuria.

Authors:  Erin L Macleod; Denise M Ney
Journal:  Ann Nestle Eng       Date:  2010-06

4.  Analysis of the functional muscle-bone unit of the forearm in patients with phenylketonuria by peripheral quantitative computed tomography.

Authors:  Daniela Choukair; Carolin Kneppo; Reinhard Feneberg; Eckhard Schönau; Martin Lindner; Stefan Kölker; Georg F Hoffmann; Burkhard Tönshoff
Journal:  J Inherit Metab Dis       Date:  2016-11-22       Impact factor: 4.982

5.  Impact of Dietary Intake on Bone Turnover in Patients with Phenylalanine Hydroxylase Deficiency.

Authors:  Kathryn E Coakley; Eric I Felner; Vin Tangpricha; Peter W F Wilson; Rani H Singh
Journal:  JIMD Rep       Date:  2017-01-28

6.  Bone metabolism and the muscle-bone relationship in children, adolescents and young adults with phenylketonuria.

Authors:  Piotr Adamczyk; Aurelia Morawiec-Knysak; Paweł Płudowski; Beata Banaszak; Jacek Karpe; Wojciech Pluskiewicz
Journal:  J Bone Miner Metab       Date:  2010-08-13       Impact factor: 2.626

7.  Modeling correlates of low bone mineral density in patients with phenylalanine hydroxylase deficiency.

Authors:  Kathryn E Coakley; Teresa D Douglas; Michael Goodman; Usha Ramakrishnan; Steven F Dobrowolski; Rani H Singh
Journal:  J Inherit Metab Dis       Date:  2016-02-16       Impact factor: 4.982

Review 8.  The complete European guidelines on phenylketonuria: diagnosis and treatment.

Authors:  A M J van Wegberg; A MacDonald; K Ahring; A Bélanger-Quintana; N Blau; A M Bosch; A Burlina; J Campistol; F Feillet; M Giżewska; S C Huijbregts; S Kearney; V Leuzzi; F Maillot; A C Muntau; M van Rijn; F Trefz; J H Walter; F J van Spronsen
Journal:  Orphanet J Rare Dis       Date:  2017-10-12       Impact factor: 4.123

9.  Low bone strength is a manifestation of phenylketonuria in mice and is attenuated by a glycomacropeptide diet.

Authors:  Patrick Solverson; Sangita G Murali; Suzanne J Litscher; Robert D Blank; Denise M Ney
Journal:  PLoS One       Date:  2012-09-18       Impact factor: 3.240

Review 10.  Selenium in bone health: roles in antioxidant protection and cell proliferation.

Authors:  Huawei Zeng; Jay J Cao; Gerald F Combs
Journal:  Nutrients       Date:  2013-01-10       Impact factor: 5.717

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.